{"id":1276,"date":"2007-10-04T10:25:36","date_gmt":"2007-10-04T17:25:36","guid":{"rendered":"http:\/\/www.carlsbadistan.com\/?p=1276"},"modified":"2007-10-04T10:25:47","modified_gmt":"2007-10-04T17:25:47","slug":"isis-pharmaceuticals-new-drug-may-work","status":"publish","type":"post","link":"http:\/\/www.carlsbadistan.com\/?p=1276","title":{"rendered":"ISIS Pharmaceuticals New Drug May Work"},"content":{"rendered":"<p>Our favorite Carlsbad-based &#8220;biopharmaceutical company&#8221; <strong><a href=\"http:\/\/www.isispharm.com\/\" target=\"_blank\">ISIS<\/a><\/strong> announced today that the test results from their new ISIS 301012, a drug designed to lower bad cholesterol in patients who suffer from &#8220;hypercholesterolemia or HeFH,&#8221; suggest that it provided &#8220;meaningful reductions in Lp(a).&#8221; And apparently, this is a good thing<\/p>\n<blockquote><p>According to <strong>Evan Stein<\/strong>, a principal investigator for the studies, the performance of ISIS 301012 continues to be extremely encouraging . . . ISIS 301012 reduces the production of apoB-100, a protein critical to the synthesis and transport of &#8220;bad&#8221; cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches. <\/p><\/blockquote>\n<p>The stock today, however, was trading down.<\/p>\n<p><strong>[Link: <\/strong><strong><a href=\"http:\/\/ir.isispharm.com\/releasedetail.cfm?ReleaseID=267339\" target=\"_blank\">ISIS Pharm<\/a><\/strong><strong> via <\/strong><strong><a href=\"http:\/\/www.rttnews.com\/sp\/breakingnews.asp?item=95\" target=\"_blank\">RTTnews<\/a><\/strong><strong>]<\/strong> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our favorite Carlsbad-based &#8220;biopharmaceutical company&#8221; ISIS announced today that the test results from their new ISIS 301012, a drug designed to lower bad cholesterol in patients who suffer from &#8220;hypercholesterolemia or HeFH,&#8221; suggest that it provided &#8220;meaningful reductions in Lp(a).&#8221; And apparently, this is a good thing According to Evan Stein, a principal investigator for [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[8,34],"tags":[],"_links":{"self":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts\/1276"}],"collection":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1276"}],"version-history":[{"count":0,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts\/1276\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1276"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}